70,213 Shares in Insulet Co. (NASDAQ:PODD) Acquired by Caisse DE Depot ET Placement DU Quebec

Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Insulet Co. (NASDAQ:PODD) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 70,213 shares of the medical instruments supplier’s stock, valued at approximately $16,342,000.

A number of other large investors have also recently made changes to their positions in PODD. Tidal Investments LLC increased its stake in shares of Insulet by 58.8% during the first quarter. Tidal Investments LLC now owns 4,064 shares of the medical instruments supplier’s stock worth $697,000 after buying an additional 1,504 shares during the period. DekaBank Deutsche Girozentrale raised its holdings in Insulet by 7.1% during the first quarter. DekaBank Deutsche Girozentrale now owns 11,607 shares of the medical instruments supplier’s stock worth $1,996,000 after purchasing an additional 770 shares in the last quarter. GAMMA Investing LLC raised its holdings in Insulet by 271.1% during the second quarter. GAMMA Investing LLC now owns 1,336 shares of the medical instruments supplier’s stock worth $270,000 after purchasing an additional 976 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in Insulet by 159.2% during the second quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 156 shares in the last quarter. Finally, Mather Group LLC. raised its holdings in Insulet by 50.3% during the second quarter. Mather Group LLC. now owns 469 shares of the medical instruments supplier’s stock worth $95,000 after purchasing an additional 157 shares in the last quarter.

Analyst Ratings Changes

PODD has been the topic of a number of research reports. Canaccord Genuity Group raised their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Citigroup raised their target price on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. UBS Group raised their target price on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Sanford C. Bernstein initiated coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Finally, Barclays raised their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Trading Down 0.1 %

Shares of PODD stock opened at $266.78 on Monday. The firm has a 50-day moving average price of $244.40 and a 200 day moving average price of $214.14. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.40. The company has a market capitalization of $18.71 billion, a price-to-earnings ratio of 45.68, a PEG ratio of 4.08 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.